Phase I study of DMP 840 in pediatric patients with refractory solid tumors

Abstract
The bis-naphthalimide DMP 840 has demonstrated high level antitumor activity in a number of preclinical models and has been evaluated in several Phase I studies in adults. We enrolled 10 patients...

This publication has 3 references indexed in Scilit: